Avidity biosciences announces completion of enrollment for harbor™, the first global phase 3 trial of delpacibart etedesiran (del-desiran) for treatment of dm1 and provides guidance on regulatory submission

-- topline data readout from harbor study anticipated in q2 2026 -- -- marketing application submissions for del-desiran including in u.s., eu and japan anticipated to start in h2 2026; on track to potentially be the first globally approved drug for dm1-- -- on track to share updates from ongoing marina-ole™ trial of del-desiran including long-term 4 mg/kg efficacy and safety data in q4 2025 -- san diego , july 28, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the completion of enrollment in the ongoing global phase 3 harbor™ clinical trial of delpacibart etedesiran (del-desiran) for people living with myotonic dystrophy type 1 (dm1). topline data from harbor, the first global phase 3 clinical trial in dm1, are anticipated in the second quarter of 2026.
RNA Ratings Summary
RNA Quant Ranking